ArticlePharmaceutics2019
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Effect of Low-Molecular-Weight Hyaluronate-Based Nanoparticles on the In Vitro Expression of Cartilage Markers.International journal of molecular sciences · 2024Article
- The multivalency game ruling the biology of immunity.Biophysics reviews · 2023Review
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug delivery and translational research · 2023Review
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- Hyaluronic Acid-Dexamethasone Nanoparticles for Local Adjunct Therapy of Lung Inflammation.International journal of molecular sciences · 2021Article
- Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach.Antibiotics (Basel, Switzerland) · 2021Review
- Novel Approaches for the Treatment of Pulmonary Tuberculosis.Pharmaceutics · 2020Review
- Advances in Pulmonary Drug Delivery.Pharmaceutics · 2020Article
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis resistant cases have been estimated to grow every year. Besides
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.